Treatment of Refractory Metastatic Renal Cell Carcinoma

SIMPLE SUMMARY: The treatment of metastatic renal cell carcinoma continues to rapidly evolve, with various combinations of immune checkpoint inhibitors and targeted tyrosine kinase inhibitors improving outcomes in the first-line setting. However, a significant subset of patients fail to respond to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vento, Joseph A., Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599552/
https://www.ncbi.nlm.nih.gov/pubmed/36291789
http://dx.doi.org/10.3390/cancers14205005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599552/
https://www.ncbi.nlm.nih.gov/pubmed/36291789
http://dx.doi.org/10.3390/cancers14205005

Ejemplares similares